Bardoxolone improves kidney function in type 2 diabetes

Nature Reviews Nephrology

Volumn 7, Issue 10, 2011, Pages 552-553

  Thomas, Merlin C ^a   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; PLACEBO; CREATININE; DRUG DERIVATIVE; METHYL 2 CYANO 3,12 DIOXOOLEAN 1,9 DIEN 28 OATE; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; OLEANOLIC ACID; TRANSCRIPTION FACTOR NRF2;

CHRONIC KIDNEY DISEASE; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DETOXIFICATION; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC DETOXICATION, DRUG; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID;

EID: 80053358983     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.114     Document Type: Note

References (10)

1. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States [online], http:// www.usrds.org/atlas-2004. htm (2004).
2. Pergola, P. E.; et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol. 33, 469-476 (2011).
3. Jiang, T.; et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59, 850-860 (2010).
4. Yoh, K.; et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 13, 1159-1170 (2008).
5. Ungvari, Z.; et al. Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. Am. J. Physiol. Heart Circ. Physiol. 300, H1133-H1140 (2011).
6. Xue, M.; et al. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 57, 2809-2817 (2008).
7. Meyer, C. J. Bardoxolone, a novel oral anti-inflammatory agent shown to improve renal function [abstract]. Am. J. Kidney Dis. 53, a129 (2009).
8. Wang, H.; et al. Heme oxygenase metabolites inhibit tubuloglomerular feedback in vivo. Am. J. Physiol. Heart Circ. Physiol. 300, H1320-H1326 (2011).
9. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials.gov/ct2/ show/NCT01351675?term=nct01351675&ra nk=1 (2011).
10. Brenner, B. M.; et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).